NKP-1339 (Synonyms: KP1339) |
| Catalog No.GC19263 |
NKP-1339 (IT-139; KP-1339) es el primer agente anticancerÍgeno a base de rutenio en su clase en desarrollo contra el cÁncer sÓlido con efectos secundarios limitados. NKP-1339 induce la detenciÓn del ciclo celular G2/M, el bloqueo de la sÍntesis de ADN y la inducciÓn de la apoptosis a través de la vÍa mitocondrial. NKP-1339 tiene un alto potencial para atacar tumores, se une fuertemente a proteÍnas séricas como la albÚmina y la transferrina y se activa en el medio tumoral reductor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 197723-00-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NKP-1339(IT-139) is a ruthenium(iii) coordination anticancer compound based on target to transferrin.
References:
[1]. Kuhn PS, et al. Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential. Dalton Trans. 2014 Nov 11.
[2]. Robert Trondl, et al. ChemInform Abstract: NKP-1339, the First Ruthenium-Based Anticancer Drug on the Edge to Clinical Application.
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *